{"id":9246,"date":"2025-07-28T07:20:48","date_gmt":"2025-07-28T12:20:48","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9246"},"modified":"2025-07-28T07:26:51","modified_gmt":"2025-07-28T12:26:51","slug":"nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/","title":{"rendered":"Se presentar\u00e1n datos sobre terapias con nanoscopios en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Americana de Especialistas en Retina de 2025."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Resultados de 126 semanas del estudio de seguimiento RESTORE (REMAIN) para destacar la eficacia y seguridad extendidas de la terapia optogen\u00e9tica MCO-010 de Nanoscope para la retinosis pigmentaria.<\/i><\/h3>

DALLAS<\/span><\/span>,\u00a028 de julio de 2025<\/span><\/span>\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscope Therapeutics Inc.,<\/a>\u00a0Una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas independientes para pacientes que sufren una p\u00e9rdida grave de la visi\u00f3n debido a enfermedades degenerativas de la retina, anunci\u00f3 que su plataforma de terapia g\u00e9nica de opsina multicaracter\u00edstica (MCO) ser\u00e1 presentada en una presentaci\u00f3n del Dr.\u00a0David S. Liao<\/span>\u00a0en el\u00a0Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Americana de Especialistas en Retina 2025<\/a>, teniendo lugar\u00a0Del 30 de julio al 2 de agosto de 2025<\/span>\u00a0en el Centro de Convenciones de Long Beach, en Long Beach, California.<\/p>

El Dr. Liao presentar\u00e1 datos de 126 semanas sobre la s\u00f3lida eficacia y el perfil de seguridad de MCO-010 en el tratamiento de pacientes con retinosis pigmentaria (RP) mediante una inyecci\u00f3n intrav\u00edtrea \u00fanica en la consulta, sin necesidad de pruebas gen\u00e9ticas.\u00a0Nanoscope inici\u00f3 recientemente un proceso continuo de presentaci\u00f3n de una solicitud de licencia para productos biol\u00f3gicos.<\/a>\u00a0(BLA) a la FDA para MCO-010 para el tratamiento de la p\u00e9rdida grave de visi\u00f3n debido a la retinosis pigmentaria. Los datos, del estudio de seguimiento RESTORE (REMAIN) de Nanoscope, constituyen la base de la solicitud de BLA presentada de forma continua por Nanoscope.<\/p>

Los detalles de la presentaci\u00f3n son los siguientes:<\/p>

T\u00edtulo:<\/b>\u00a0 \u00a0 \u00a0<\/span><\/p><\/td>

Eficacia y seguridad prolongadas de la terapia optogen\u00e9tica MCO-010 para la retinosis pigmentaria: resultados a las 126 semanas del estudio de seguimiento RESTORE (REMAIN).<\/span><\/p><\/td><\/tr>

T\u00edtulo de la sesi\u00f3n<\/b>:\u00a0<\/span><\/p><\/td>

Simposio 1 sobre Enfermedades Retinianas Hereditarias y Gen\u00e9tica<\/span><\/p><\/td><\/tr>

Fecha de la sesi\u00f3n:<\/b><\/span><\/p><\/td>

Viernes, 1 de agosto<\/span><\/p><\/td><\/tr>

Tiempo de sesi\u00f3n:<\/b><\/span><\/p><\/td>

De 16:50 a 16:53 PDT<\/span><\/p><\/td><\/tr>

Presentador:<\/b>\u00a0<\/span><\/p><\/td>

David S. Liao, MD, Ph.D., especialista en enfermedades de la retina y el v\u00edtreo, Grupo M\u00e9dico Retina-Vitreous Associates<\/a><\/span><\/p><\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div>

\u201cEstamos entusiasmados de que estos datos de 126 semanas se presenten en ASRS, especialmente con nuestro reciente anuncio de BLA\u201d, dijo\u00a0Dr.\u00a0Samuel Barone<\/span>, Director M\u00e9dico de Nanoscope.<\/a>\u00a0 \u201cEsta ser\u00e1 una gran oportunidad para que la comunidad de ASRS discuta nuestros datos y su impacto potencial en los pacientes con retinosis pigmentaria.\u201d<\/p>

Para obtener m\u00e1s informaci\u00f3n sobre MCO-010 y Nanoscope Therapeutics, visite:\u00a0www.nanostherapeutics.com<\/a>.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica independiente del gen que restaura la visi\u00f3n para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos de la fase RESTORE\u00a02b<\/span>\u00a0Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD. Los programas precl\u00ednicos incluyen amaurosis cong\u00e9nita de Leber (LCA), en estudios precl\u00ednicos, as\u00ed como un f\u00e1rmaco listo para la solicitud de IND para atrofia geogr\u00e1fica (GA).<\/p>

Contacto:
<\/b>Terap\u00e9utica del nanoscopio
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

126-week results from RESTORE follow-up study (REMAIN) to highlight the extended efficacy and safety of Nanoscope\u2019s MCO-010 optogenetic therapy for Retinitis Pigmentosa DALLAS,\u00a0July 28, 2025\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscope Therapeutics Inc.,\u00a0a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative diseases, announced that its multi-characteristic opsin (MCO) gene […]<\/p>\n","protected":false},"author":6,"featured_media":9247,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-28T12:20:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-28T12:26:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting\",\"datePublished\":\"2025-07-28T12:20:48+00:00\",\"dateModified\":\"2025-07-28T12:26:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"},\"wordCount\":455,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_ASRS_2025_REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_ASRS_2025_REV.jpg\",\"datePublished\":\"2025-07-28T12:20:48+00:00\",\"dateModified\":\"2025-07-28T12:26:51+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_ASRS_2025_REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_ASRS_2025_REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/28\\\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Datos sobre terapias con nanoscopios que se presentar\u00e1n en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Estadounidense de Especialistas en Retina de 2025 - Terapias con nanoscopios","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-07-28T12:20:48+00:00","article_modified_time":"2025-07-28T12:26:51+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting","datePublished":"2025-07-28T12:20:48+00:00","dateModified":"2025-07-28T12:26:51+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/"},"wordCount":455,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_ASRS_2025_REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/","url":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/","name":"Datos sobre terapias con nanoscopios que se presentar\u00e1n en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Estadounidense de Especialistas en Retina de 2025 - Terapias con nanoscopios","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_ASRS_2025_REV.jpg","datePublished":"2025-07-28T12:20:48+00:00","dateModified":"2025-07-28T12:26:51+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_ASRS_2025_REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_ASRS_2025_REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/28\/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9246"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9246\/revisions"}],"predecessor-version":[{"id":9252,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9246\/revisions\/9252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/9247"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}